教育经历 2000.9～2004.6 浙江大学医学院，生理学博士 1988.9～1992.7 浙江医科大学药学系，药物分析学硕士 1982.8～1986.7 浙江医科大学药学系，理学学士 国外学习与研究经历 2007.1～2008.12 美国密歇根大学药学院访问学者 1998.9～1999.2 日本歧阜药科大学访问学者 工作经历 2005.12～现在 浙江大学药学院，教授 1997.12～2005.12 浙江医科大学、浙江大学药学院，副教授 1992.12～1997.12 浙江医科大学药学系，讲师 1986.8～1992.12 浙江医科大学药学系，助教 奖励荣誉 姚建标，徐春玲，蒋惠娣，朱纲，毕真真，金辉辉，马志媛.中药大品种普乐安上市后技术提升及国际化应用.浙江省科技进步三等奖，2022. 曾苏，侯廷军，余露山，何俏军，蒋惠娣，杨波，周慧，胡海红，徐思云，陈枢青，罗沛华，李丹. ADMET成药性评价关键技术和模型研究. 高校科学研究优秀成果奖科技进步奖，二等奖，2014. 曾苏，余露山，蒋惠娣，姚彤炜，陈枢青，等. 手性药物分析与手性药物代谢. 浙江省科技技术奖二等奖，2012. 曾苏，蒋惠娣，余露山，姚彤炜，刘瑶，等. 中药代谢分析技术平台建立与应用. 浙江省科技进步二等奖，2010. 蒋惠娣，曾苏，夏强，王如伟，李丽萍，等. 杭白菊抗心肌缺血中药新药的开发研究. 浙江省科学技术二等奖，2008. 姚彤炜，曾苏，陈枢青，蒋惠娣，等. 中药与天然药物代谢活性筛选技术平台研究，浙江省中医药科学技术创新奖一等奖，2007.

药物/生理活性物质的转运与代谢研究 中药体内过程及物质基础研究 创新药物非临床药代动力学研究

代表论文（2011-） Luo J, Li P, Dong M, Zhang Y, Lu S, Chen M, Zhou H, Lin N, Jiang H*, Wang Y*. SLC15A3 plays a crucial role in pulmonary fibrosis by regulating macrophage oxidative stress. Cell Death Differ, 2024,31(4):417-30. Zhang Y, Chen Y, Chen X, Gao Y, Luo J, Lu S, Li Q, Li P, Bai M, Jiang T, Zhang N, Zhang B, Chen B, Zhou H, Jiang H*, Lin N*. Unconjugated bilirubin promotes uric acid restoration by activating hepatic AMPK pathway. Free Radic Biol Med, 2024, 224:644-59. Dong M, Li P, Luo J, Chen B, Jiang H*. Oligopeptide/Histidine Transporter PHT1 and PHT2 - Function, Regulation, and Pathophysiological Implications Specifically in Immunoregulation. Pharm Res, 2023,40(11):2585-96. Yi Y, Zhang H, Chen M, Chen B, Chen Y, Li P, Zhou H, Ma Z, Jiang H*. Inhibition of multiple uptake transporters in cardiomyocytes/mitochondria alleviates doxorubicin-induced cardiotoxicity. Chem Biol Interact, 2023,382:110627. Chen Y, Lu S, Zhang Y, Chen B, Zhou H, Jiang H*. Examination of the emerging role of transporters in the assessment of nephrotoxicity. Expert Opin Drug Metab Toxicol, 2022,18(11):787-804. Bai M#, Chen M#, Zeng Q, Lu S, Li P, Ma Z, Lin N, Zheng C, Zhou H, Zeng S, Sun D*, Jiang H*. Up-regulation of hepatic CD36 by increased corticosterone/cortisol via glucocorticoid receptor contributes to liver lipid accumulation and hypertriglyceridemia during pregnancy. Br J Pharmacol. 2022, 179(17):4440-56. Zhang Y, Chen Y, Dai B, Bai M, Lu S, Lin N, Zhou H, Jiang H*. Bilirubin reduces the uptake of estrogen precursors and the followed synthesis of estradiol in human placental syncytiotrophoblasts via inhibition and down-regulation of OAT4. Drug Metab Dispos. 2022,50(4):341-50. Li P, Chen X, Dong M, Luo J, Lu S, Chen M, Zhang Y, Zhou H, Jiang H*. Gut inflammation exacerbates high-fat diet induced steatosis by suppressing VLDL-TG secretion through HNF4α pathway. Free Radic Biol Med. 2021,172:459-469. Yi Y, Li L, Song F, Li P, Chen M, Ni S, Zhang H, Zhou H, Zeng S, Jiang H*. L-tetrahydropalmatine reduces oxaliplatin accumulation in the dorsal root ganglion and mitochondria through selectively inhibiting the transporter-mediated uptake thereby attenuates peripheral neurotoxicity. Toxicology. 2021, 459:152853. Li P, Wang Y, Luo J, Zeng Q, Wang M, Bai M, Zhou H, Wang J*, Jiang H*. Downregulation of OCTN2 by cytokines plays an important role in the progression of inflammatory bowel disease. Biochem Pharmacol. 2020,178,114115 Li C, Li L, Yi Y, Wang W, Yuan J, Tan F, Fang D, Zeng S, Zhou H*, Jiang H*. L-THP attenuates cisplatin-induced nephrotoxicity without impairing its anticancer efficacy via selective inhibition of OCT2. Biochem Pharmacol.2020,177,114021. Lu S, Yang X, Jiang T, Zhou H, Wang W, Lin N, Zeng S, Ma Z*, Jiang H*. Pregnancy impacts entecavir pharmacokinetics but does not alter its renal excretion, J Pharm Sci, 2020, 109(5): 1811-1818. Ma Z#, Lu S#, Sun D, Bai M, Jiang T, Lin N, Zhou H, Zeng S, Jiang H*. Roles of OAT2 and ENT1 in hepatic disposition and antiviral activity of entecavir during non-Pregnancy and pregnancy. Br J Pharmacol. 2019,176:3236-3249. Bai M, Zeng Q, Chen Y, Chen M, Li P, Ma ZY Sun D, Zhou H, Zheng C, Zeng S, Jiang H*. Maternal plasma L-carnitine reduction during pregnancy is mainly attributed to octn2-mediated placental uptake and does not result in maternal hepatic fatty acid β-oxidation decline. Drug Metab Dispos. 2019,47(6):582-591. Wang W#, Bai M#, Jiang T, Li C, Li P, Zhou H, Wang Z, Li L, Jiang H*. Clozapine-induced reduction of L-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. Toxicol Appl Pharmacol.2019,363:47-56. Wang Y, Li P, Song F, Yang X, Weng Y, Ma Z, Wang L, Jiang H*. Substrate transport properties of the human peptide/histidine transporter PHT2 in transfected MDCK cells. J Pharm Sci, 2019,108:3416-3424. Jiang T, Zhang Y, Bai M, Li P, Wang W, Chen M, Ma Z, Zeng S, Zhou H*, Jiang H*. Olanzapine -induced liver steatosis is involved in up-regulation of hepatic fatty acid transporters and down-regulation of OCTN2. Toxicol Lett. 2019,316:1783-93. Wang Y, Hu Y, Li P, Weng Y, Kamada N, Jiang H*, Smith DE*. Expression and regulation of proton-coupled oligopeptide transporters in colonic tissue and immune cells of mice. Biochem Pharmacol. 2018, 148:163-73. Song F, Hu Y, Wang Y, Smith DE, Jiang H*. Functional characterization of human peptide/histidine transporter 1 in stably transfected MDCK cells. Mol Pharm. 2018, 15(2):385-93. Song F, Yi Y, Li C, Hu Y, Wang J, Smith DE, Jiang H*. Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage. Cell Death Dis, 2018,9(7):770.